Hologic (HOLX) Issues Q2 Earnings Guidance

Share on StockTwits

Hologic (NASDAQ:HOLX) issued an update on its second quarter earnings guidance on Wednesday morning. The company provided EPS guidance of $0.55-0.57 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.58. The company issued revenue guidance of $795-810 million, compared to the consensus revenue estimate of $812.77 million.Hologic also updated its FY 2019 guidance to $2.39-2.43 EPS.

Shares of HOLX stock traded down $0.66 during trading hours on Thursday, hitting $44.35. 223,241 shares of the company were exchanged, compared to its average volume of 2,205,370. The company has a quick ratio of 0.95, a current ratio of 1.23 and a debt-to-equity ratio of 1.12. Hologic has a 52-week low of $35.10 and a 52-week high of $45.28. The firm has a market cap of $12.84 billion, a P/E ratio of 19.90, a PEG ratio of 2.03 and a beta of 0.73.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Wednesday, January 30th. The medical equipment provider reported $0.58 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.57 by $0.01. Hologic had a negative net margin of 3.46% and a positive return on equity of 23.52%. The company had revenue of $830.70 million during the quarter, compared to analyst estimates of $823.22 million. During the same quarter last year, the business posted $0.55 EPS. Hologic’s quarterly revenue was up 5.0% compared to the same quarter last year. As a group, equities analysts expect that Hologic will post 2.4 EPS for the current year.

HOLX has been the subject of several research analyst reports. Canaccord Genuity restated a hold rating and set a $41.00 price target on shares of Hologic in a research note on Monday, January 7th. BidaskClub upgraded shares of Hologic from a buy rating to a strong-buy rating in a research note on Wednesday, November 21st. Piper Jaffray Companies raised their price target on shares of Hologic to $49.00 and gave the stock an overweight rating in a research note on Thursday. UBS Group assumed coverage on shares of Hologic in a research note on Tuesday, October 9th. They issued a neutral rating and a $44.00 price objective for the company. Finally, Zacks Investment Research lowered shares of Hologic from a hold rating to a sell rating in a research note on Tuesday, October 9th. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating, five have given a buy rating and one has given a strong buy rating to the company. Hologic currently has an average rating of Hold and an average target price of $43.89.

In other news, insider Benjamin Jordan Cohn sold 10,000 shares of the business’s stock in a transaction on Friday, November 30th. The shares were sold at an average price of $44.49, for a total transaction of $444,900.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Allison P. Bebo sold 6,500 shares of the business’s stock in a transaction on Friday, November 16th. The shares were sold at an average price of $42.00, for a total transaction of $273,000.00. The disclosure for this sale can be found here. Insiders sold a total of 36,355 shares of company stock valued at $1,584,655 over the last quarter. 0.90% of the stock is owned by company insiders.

COPYRIGHT VIOLATION WARNING: This piece was originally posted by Ticker Report and is the property of of Ticker Report. If you are viewing this piece on another domain, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.tickerreport.com/banking-finance/4115887/hologic-holx-issues-q2-earnings-guidance.html.

Hologic Company Profile

Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.

Featured Article: The components of the Stochastic Momentum Index

Earnings History and Estimates for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Pebblebrook Hotel Trust  Increases Dividend to $0.38 Per Share
Pebblebrook Hotel Trust Increases Dividend to $0.38 Per Share
APN Industria REIT  To Go Ex-Dividend on March 28th
APN Industria REIT To Go Ex-Dividend on March 28th
Volution Group PLC  Announces Dividend of GBX 1.60
Volution Group PLC Announces Dividend of GBX 1.60
Insider Selling: Ambarella Inc  VP Sells 3,700 Shares of Stock
Insider Selling: Ambarella Inc VP Sells 3,700 Shares of Stock
iShares Morningstar Mid-Cap Value ETF  Shares Bought by MML Investors Services LLC
iShares Morningstar Mid-Cap Value ETF Shares Bought by MML Investors Services LLC
Zacks: Analysts Expect Cloudera Inc  Will Announce Earnings of -$0.23 Per Share
Zacks: Analysts Expect Cloudera Inc Will Announce Earnings of -$0.23 Per Share


© 2006-2019 Ticker Report